Cryptococcal infection in patients with haematological and solid organ malignancy in the era of targeted and immune-based therapies

Affiliations

¹ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
² National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead and The University of Sydney, Sydney, New South Wales, Australia.
³ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
⁴ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
⁵ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Electronic address: ben.teh@petermac.org.

Free article

Comment

V Madigan et al. Clin Microbiol Infect. 2020 Apr.

Free article

. 2020 Apr;26(4):519-521.

doi: 10.1016/j.cmi.2019.10.028. Epub 2019 Nov 5.

¹ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.
² National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead and The University of Sydney, Sydney, New South Wales, Australia.
³ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
⁴ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
⁵ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Electronic address: ben.teh@petermac.org.

No abstract available

Comment on

Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies.
Teh BW, Tam CS, Handunnetti S, Worth LJ, Slavin MA. Teh BW, et al. Blood Rev. 2018 Nov;32(6):499-507. doi: 10.1016/j.blre.2018.04.007. Epub 2018 Apr 23. Blood Rev. 2018. PMID: 29709246 Review.